ABI-4334 is under clinical development by Assembly Biosciences and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ABI-4334’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ABI-4334 overview

ABI-4334 is under development for the treatment of chronic hepatitis B infections and hepatitis D. It is administered through oral route in the form of tablets. The drug candidate acts by targeting capsid protein.

Assembly Biosciences overview

Assembly Biosciences (Assembly) is a biotechnology company that develops, discovers and commercializes small molecule therapies. The company develops therapies for the treatment of viral diseases. Its pipeline products include ABI-5366- HSV-2 Long Acting Helicase Inhibitor. It also offers HBV/HDV Entry Inhibitor, Interferon- a Receptor Against, ABI-H3733 and ABI-4334 among others. The company owns and operates in New York, Indiana and California, the US. Assembly is headquartered in South San Francisco, the US.

For a complete picture of ABI-4334’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.